Patents by Inventor Craig E. Masse

Craig E. Masse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150025093
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 25, 2014
    Publication date: January 22, 2015
    Applicant: Nimbus Iris, Inc.
    Inventors: Donna L. Romero, Matthew David Wessel, Shaughnessy Robinson, Jeremy Robert Greenwood, Karl Shawn Watts, Leah Lynn Frye, Geraldine C. Harriman, Alan Franklin Corin, Craig E. Masse, Mee Shelley
  • Publication number: 20140221492
    Abstract: This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.
    Type: Application
    Filed: March 20, 2014
    Publication date: August 7, 2014
    Inventor: Craig E. Masse
  • Publication number: 20140194417
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Nimbus Iris, Inc.
    Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Rosana Kapeller-Libermann, Craig E. Masse, Shaughnessy Robinson, Donna L. Romero, Mee Shelley, Ronald T. Wester
  • Patent number: 8765723
    Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: July 1, 2014
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
  • Publication number: 20140155444
    Abstract: This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.
    Type: Application
    Filed: October 21, 2013
    Publication date: June 5, 2014
    Applicant: Concert Pharmaceuticals Inc.
    Inventors: Roger Tung, Craig E. Masse, Bhaumik A. Pandya
  • Patent number: 8703941
    Abstract: The present invention provides thienopyrimidine and thienopyridine compounds, compositions thereof, and methods of using the same for the treatment of diseases mediated by IRAK enzymes. Such diseases include inflammatory and proliferative diseases.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: April 22, 2014
    Assignee: Nimbus Iris, Inc.
    Inventors: Donna L. Romero, Matthew David Wessel, Shaughnessy Robinson, Jeremy Robert Greenwood, Karl Shawn Watts, Leah Lynn Frye, Geraldine C. Harriman, Alan Franklin Corin, Craig E. Masse, Mee Shelley
  • Patent number: 8704001
    Abstract: This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: April 22, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Craig E. Masse
  • Publication number: 20140018379
    Abstract: The present invention provides a compound of Formula I or Formula VI: as defined herein. The invention is also directed to compositions comprising the compound of Formula I or Formula VI and methods of therapeutic treatment using the compound of Formula I or Formula VI.
    Type: Application
    Filed: February 18, 2011
    Publication date: January 16, 2014
    Applicant: CONCERT PHARMACEUTICALS INC.
    Inventors: Roger Tung, Craig E. Masse
  • Publication number: 20140018361
    Abstract: The present invention provides furano- and pyrrolo-pyrimidine and pyridine compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 16, 2014
    Inventors: Geraldine C. Harriman, Donna L. Romero, Craig E. Masse, Shaughnessy Robinson, Matthew David Wessel, Jeremy Robert Greenwood
  • Publication number: 20140018357
    Abstract: The present invention provides thienopyridine compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 16, 2014
    Inventors: Geraldine C. Harriman, Ronald T. Wester, Donna L. Romero, Craig E. Masse, Shaughnessy Robinson, Jeremy Robert Greenwood
  • Publication number: 20140005211
    Abstract: This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
    Type: Application
    Filed: September 3, 2013
    Publication date: January 2, 2014
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventors: Bhaumik Pandya, Craig E. Masse, Ian Robert Silverman, Roger Tung
  • Patent number: 8575361
    Abstract: This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: November 5, 2013
    Assignee: Concert Pharmaceuticals Inc.
    Inventors: Roger Tung, Craig E. Masse
  • Patent number: 8575221
    Abstract: The invention relates to compounds of Formula I or Ia as disclosed herein: or pharmaceutically acceptable salts thereof or tautomers thereof.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: November 5, 2013
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Craig E. Masse, Roger D. Tung
  • Publication number: 20130281456
    Abstract: The present invention is directed to a process for preparing a 2,26,6-d4-morpholine derivative represented by Structural Formula (I): or a salt thereof.
    Type: Application
    Filed: November 15, 2012
    Publication date: October 24, 2013
    Inventors: Julie F. Liu, Xuejun Tang, Scott L. Harbeson, Craig E. Masse
  • Publication number: 20130231328
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 10, 2013
    Publication date: September 5, 2013
    Applicant: NIMBUS IRIS, INC.
    Inventors: Geraldine C. Harriman, Ronald T. Wester, Donna L. Romero, Shaughnessy Robinson, Mee Shelley, Matthew David Wessel, Jeremy Robert Greenwood, Craig E. Masse, Rosana Kapeller-Libermann
  • Patent number: 8513434
    Abstract: This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: August 20, 2013
    Assignee: Concert Pharmaceuticals Inc.
    Inventors: Roger Tung, Craig E. Masse
  • Patent number: 8410124
    Abstract: This disclosure relates to novel di-aryl-pyrimidine (DAPY) compounds and pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a non-nucleoside reverse transcriptase inhibitor (NNRTI).
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: April 2, 2013
    Assignee: Concert Pharmaceuticals Inc.
    Inventor: Craig E. Masse
  • Patent number: 8354557
    Abstract: The present invention is directed to a process for preparing a 2,26,6-d4-morpholine derivative represented by Structural Formula (I): or a salt thereof.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: January 15, 2013
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Xuejun Tang, Scott L. Harbeson, Craig E. Masse
  • Patent number: 8349817
    Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: January 8, 2013
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
  • Publication number: 20130005742
    Abstract: This invention relates to novel substituted diphenylpyrazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a PGI2 receptor agonist.
    Type: Application
    Filed: August 6, 2010
    Publication date: January 3, 2013
    Inventors: Scott L. Harbeson, Craig E. Masse, Julie F. Liu